Share This

The purpose of this review was to consider data relating to risks and benefits of the use of anti-VEGF treatment for retinopathy of prematurity (ROP) over the past five years of 2015-2020. Ocular benefits include treatment of aggressive posterior ROP, vascularisation of peripheral retina after treatment and reduced incidence of high myopia. Ocular side-effects include abnormalities in peripheral retina and posterior pole, development of retinal detachment, greater potential for later recurrence than with retinal photocoagulation, asymmetric responses / outcomes and potential for anterior segment complications. Systemic side-effects include the confirmed presence of anti-VEGF drugs in systemic circulation after intravitreal injections. Further review sections include comparison of Bevacizumab and Ranibizumab, effect of decreased dosage on anti-VEGF therapy, anti-VEGF and laser combination therapy, and current clinical trials for ROP. The authors conclude that there remains a need for a large multicentre randomised control trial (RCT) with long-term follow-up of patients receiving anti-VEGF treatment for type I ROP and addressing the efficacy and safety of various anti-VEGF drugs.

Update on the use of anti-VEGF drugs in the treatment of retinopathy of prematurity.
Seery CW, Betesh S, Guo S, et al.
Share This
Fiona Rowe (Prof)

Institute of Population Health, University of Liverpool, UK.

View Full Profile